👾AIST: Aiming at sugar chains on the surface of pancreatic cancer cells with lectin fusogenic drugs: 2017/09/26

By AIST, JPN

👾AIST: Aiming at sugar chains on the surface of pancreatic cancer cells with lectin fusogenic drugs: 2017/09/26

Development of novel anticancer therapy as a post-antibody drug
Points of Research Results

  1. We discovered a sugar chain 1) strongly expressed on the surface of pancreatic cancer cells, which is a representative of intractable cancer, and a lectin 2) (a protein with sugar chain binding ability) that specifically recognizes it.
  2. LDC (Lectin Drug Conjugate), which fused an anti-cancer drug to lectin, confirmed that mouse can safely be administered to living body without side effects such as blood coagulation.
  3. We succeeded in treating various mouse pancreatic cancer models by a novel approach of targeting sugar chains covering the outermost layer of cells with lectin.
  4. Showed the possibility that lectin could become an influential drug carrier as an inexpensive post-antibody drug replacing expensive antibody therapeutics.

http://www.aist.go.jp/aist_j/press_release/pr2017/pr20170926/pr20170926.html

More from tokioX :

  1. 💡AIST: Tungsten oxide based gas chromic photoresist film that can be produced at ambient temperature and atmosphere
  2. 💡AIST: Developed a compact sensor that can repeatedly detect the occurrence of formaldehyde   20171023
  3. 💡AIST: Characteristic simulation software for thin-film solar cells is released free of charge  20170925
  4. AIST: Confirm biodegradability of super growth single wall carbon nanotube  
  5. AIST: Water repels, develops heat insulating material that does not break even if it is crushed through light   20170904
  6. AIST: World’s highest performance gallium nitride piezoelectric thin film is fabricated by RF sputtering method point   20170831
  7. AIST: Measure the state of charge in the organic EL element in real time  20170831